Intranasal CNS delivery for neurodegenerative disease
Proprietary AmyloLipid Nanovesicle technology designed to improve brain exposure of GLP-1 receptor agonists through direct nose-to-brain delivery.
CNS exposure remains a major challenge
Systemic delivery of peptide therapeutics for CNS disorders remains limited by poor brain exposure, peripheral distribution, and blood-brain barrier constraints.
Recent clinical findings in Alzheimer’s disease suggest that limited CNS exposure may contribute to insufficient therapeutic effect despite measurable biological activity.
AmyloLipid Nanovesicles
A proprietary self-assembling nanovesicle system being developed for intranasal CNS delivery of peptide therapeutics.
Proprietary ALN Platform
AmyloLipid Nanovesicles invented at Ben-Gurion University of the Negev and exclusively licensed to MacieTech Pharma.
Intranasal CNS Delivery
Designed to support direct nose-to-brain transport through olfactory-associated pathways while minimizing systemic exposure.
Translational Development
Preclinical platform evaluation across multiple published molecules, now advancing toward GLP-1RA proof of concept.
Preclinical platform evaluation
The ALN platform has been evaluated preclinically across multiple therapeutic compounds in various studies, with insulin serving as the most relevant translational reference for polypeptide delivery to the brain.
Intranasal Insulin ALNs
Insulin is a high-molecular-weight polypeptide model and provides the most relevant published preclinical bridge to MacieTech’s planned GLP-1RA formulation work.
- Brain concentrations comparable to IV and SC administration
- Substantially lower plasma exposure than parenteral routes
- Higher brain-to-plasma ratio supporting direct nose-to-brain delivery
- Relevant translational rationale for CNS peptide delivery
Alzheimer’s disease
MacieTech is developing a proprietary GLP-1RA ALN formulation designed to improve regional brain exposure and CNS delivery while minimizing systemic exposure during chronic administration.
MacieTech’s development program is structured to establish CNS exposure, biomarker modulation, and tolerability of intranasal GLP-1RA-loaded ALNs before progressing toward IND-enabling studies.
Preclinical PoC
PK/PD Studies
IND-Enabling
Early Clinical Development
Integrated drug–device development
As part of its longer-term translational development strategy, MacieTech Pharma plans to integrate a dedicated multi-dose intranasal inhaler-applicator designed to support precise, reproducible, and user-friendly administration of ALN-encapsulated therapeutics for CNS-targeted delivery, with future potential for digital and biomarker-guided administration optimization.
Future indications
MacieTech’s proprietary ALN platform is designed as a broader CNS drug delivery technology rather than a single-indication program. The olfactory delivery mechanism and nanoparticle encapsulation technology are well positioned to support future development across additional neurodegenerative and neuroinflammatory disorders where targeted brain delivery remains a major therapeutic challenge.
Parkinson’s Disease
A neurodegenerative disorder where targeted delivery to affected brain regions remains a major therapeutic challenge.
Multiple Sclerosis (MS)
A neuroinflammatory disorder of the central nervous system and a potential future direction for the ALN platform.
ALS
A neurodegenerative disease representing an additional potential CNS target for intranasal ALN delivery.
Our team
Partner with us
MacieTech Pharma welcomes discussions with translational research organizations, pharmaceutical companies, and pharma-focused investors interested in next-generation CNS delivery technologies.
This website is provided for general informational purposes only and does not constitute an offer to sell securities or make therapeutic claims regarding clinical efficacy.